<DOC>
	<DOC>NCT00366678</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in France.</brief_summary>
	<brief_title>Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy 2monthold infants. Available for the entire study period. Exclusion criteria: Â· Known contraindication to vaccines.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>98 Days</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Vaccine</keyword>
</DOC>